Kapidex Delayed Release Capsules (Dexlansoprazole Delayed Release Capsules) Drug Overview and Uses for Patients and Caregivers at RxList

Pill Identifier Search

May 27, 2012

Kapidex

Gastroesophageal Reflux Disease (GERD) »

GERD Facts

GERD is a condition in which the acidified liquid content of the stomach up into the esophagus.
The causes of GERD include an abnormal lower esophageal sphincter, hiatal hernia, abnormal esophageal contractions, and slow emptying of the stomach.
GERD may damage the lining of the esophagus, thereby causing inflammation (esophagitis), although usually it does not.
The symptoms of uncomplicated GERD are heartburn, regurgitation, and nausea.
Complications of GERD include ulcers and strictures of the esophagus, Barrett's esophagus, cough and asthma, throat and laryngeal inflammation, inflammation and infection of the lungs, and collection of fluid in the sinuses and middle ear.
Barrett's esophagus is a pre-cancerous condition that requires periodic endoscopic surveillance for the development of cancer.
GERD may be diagnosed or evaluate...

Read the Gastroesophageal Reflux Disease (GERD) article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Kapidex Delayed Release Capsules

Heartburn: Foods to Eat, Foods to Avoid Slideshow Pictures

Digestive Disease Myths Slideshow Pictures

Diverticulitis (Diverticulosis) Slideshow Pictures

font size

Kapidex (dexlansoprazole delayed release capsules) (Now known as Dexilant)
(dexlansoprazole) Delayed Release Capsules

DRUG DESCRIPTION

The active ingredient in KAPIDEX (dexlansoprazole delayed release capsules) (dexlansoprazole) delayed release capsules is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Dexlansoprazole is the R-enantiomer of lansoprazole (a racemic mixture of the R- and S-enantiomers). Its empirical formula is: C₁₆H₁₄F₃N₃O₂S, with a molecular weight of 369.36. The structural formula is:

KAPIDEX (dexlansoprazole) Structural Formula Illustration

Dexlansoprazole is a white to nearly white crystalline powder which melts with decomposition at 140°C. Dexlansoprazole is freely soluble in dimethylformamide, methanol, dichloromethane, ethanol, and ethyl acetate; and soluble in acetonitrile; slightly soluble in ether; and very slightly soluble in water; and practically insoluble in hexane.

Dexlansoprazole is stable when exposed to light. Dexlansoprazole is more stable in neutral and alkaline conditions than acidic conditions.

KAPIDEX (dexlansoprazole delayed release capsules) is supplied as a dual delayed release formulation in capsules for oral administration. The capsules contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles [see CLINICAL PHARMACOLOGY].

KAPIDEX (dexlansoprazole delayed release capsules) is available in two dosage strengths: 30 mg and 60 mg, per capsule. Each capsule contains enteric-coated granules consisting of dexlansoprazole (active ingredient) and the following inactive ingredients: sugar spheres, magnesium carbonate, sucrose, low-substituted hydroxypropyl cellulose, titanium dioxide, hydroxypropyl cellulose, hypromellose 2910, talc, methacrylic acid copolymer, polyethylene glycol 8000, triethyl citrate, polysorbate 80, and colloidal silicon dioxide. The components of the capsule shell include the following inactive ingredients: hypromellose, carrageenan and potassium chloride. Based on the capsule shell color, blue contains FD&C Blue No. 2 and aluminum lake; gray contains ferric oxide and aluminum lake; and both contain titanium dioxide.

Last reviewed on RxList: 4/14/2010
This monograph has been modified to include the generic and brand name in many instances.